Rokit Genomics Files Five Foundational Patents for Organ Rejuvenation Platform

Building an Epigenetics-Based Patent Portfolio Targeting Lung, Liver, Skin, Retina, and Kidney
Collaboration With Algenomics to Integrate circRNA and AI Bioprinting

Rokit Healthcare announced on July 16 that its subsidiary, Rokit Genomics, has filed five original patents for an epigenetics-based organ rejuvenation platform targeting the lung, liver, skin, retina, and kidney.

Rocket Healthcare company logo image. Rocket Healthcare

This patent covers a platform technology that controls organ-specific aging mechanisms epigenetically. The company explained that it has built a customized development platform for each organ by reflecting variables such as chromatin accessibility, histone modification, DNA methylation patterns, and tissue-specific transcription factor binding sites.

Rokit Genomics stated that, unlike conventional gene-editing methods such as CRISPR-Cas9 that directly cut DNA, this technology features reversible regulation of target gene expression, thereby reducing the risk of permanent genetic changes. Through this, it can be used to regulate impaired metabolic processes related to aging such as glucose and lipid metabolism, inflammation, and oxidative stress.

The company noted that, considering that the epigenetic environment of the same gene varies by organ, it has developed optimized technologies for specific organs including the lung, liver, and kidney. They expect this design to translate into patent competitiveness.

To commercialize the technology, Rokit Genomics signed a memorandum of understanding (MOU) with RNA-based gene therapy company Algenomics. The two companies are pursuing a plan to combine Rokit Genomics' epigenetics-based rejuvenation technology with Algenomics’ circular RNA (circRNA) platform. In addition, they plan to incorporate Rokit Healthcare’s AI-based bioprinting technology to develop an organ regeneration platform.

A representative from Rokit Healthcare stated, "We will expand opportunities for joint research and technology transfer based on the safety and reversibility of epigenetics-based rejuvenation technology."

This content was produced with the assistance of AI translation services.